GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSTO:ULTIo) » Definitions » Future Policy Benefits

Ultimovacs ASA (OSTO:ULTIO) Future Policy Benefits


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Ultimovacs ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.